Soligenix, Inc. (SNGX): Total Liabilities
$3.94M
As of 2025-12-31
$3.85M
As of 2026-06-30
-38.3%
3-year compound annual growth
-24.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $3.94M | -18.7% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $4.85M | -33.4% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $7.27M | -56.6% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $16.75M | +3.7% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $16.15M | 0.0% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $16.15M | +155.6% | 2022-03-29, Balance as of period end |
| 2019-12-31 | $6.32M | +50.0% | 2021-03-30, Balance as of period end |
| 2018-12-31 | $4.21M | n/a | 2020-03-30, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Soligenix, Inc. (SNGX) | 2025-12-31 | $3.94M | -18.7% |
| ProMIS Neurosciences Inc. (PMN) | 2025-12-31 | $10.44M | +330.9% |
| Indaptus Therapeutics, Inc. (INDP) | 2024-12-31 | $3.39M | +19.2% |
| Kala Bio, Inc. (KALA) | 2025-12-31 | $2.49M | -94.2% |
| Earth Science Tech, Inc. (ETST) | 2026-03-31 | $1.93M | -40.0% |
| FibroBiologics, Inc. (FBLG) | 2025-12-31 | $3.46M | -74.7% |
| Nanoviricides, Inc. (NNVC) | 2025-06-30 | $1.30M | -4.3% |
| MAIA Biotechnology, Inc. (MAIA) | 2025-12-31 | $7.33M | +12.4% |
| Cocrystal Pharma, Inc. (COCP) | 2025-12-31 | $3.38M | -14.0% |
Compare SNGX, PMN, INDP, KALA side by side · Screen every company in Pharmaceutical Preparations ↗